result in indeterminate or unreportable results and there is no clear guidance on managing them. Aim: To quantify the prevalence of indeterminate or unreportable TB IGRA Elispot results in a large tertiary centre cohort of patients with IBD. Methods: We performed a single centre retrospective study of IGRA tests performed on IBD patients prior to commencement of anti-TNF therapy between Oct 2010 and Oct 2013. Results: 140 patients were included (median age 34, range 24 86, 50% males). 92% had Crohn's disease (CD), 4% ulcerative colitis (UC), and 4% IBD-unclassified. At the time of IGRA testing, 115 patients were on immunomodulators (81 azathioprine, 11 mercaptopurine, 2 tioguanine, 11 methotrexate) or prednisolone (6). Three patients were positive for latent TB infection at screening and were referred to the infectious disease (ID) department prior to anti-TNF therapy. Three patients had indeterminate results; all were on immunosuppressants (2 azathioprine, 1 methotrexate). 2 had a lymphocyte count <1. In 2 cases the IGRA was repeated, one was negative and the second was unreportable on 2 occasions. None had TB risk factors and all were started on anti-TNF. To date, none have developed TB (follow up range 6 18 months). Ten patients had unreportable results, 9 of whom were taking azathioprine. On repeat testing, 4 were negative, and the remainder were still unreportable, one of whom had risk factors for TB and was treated with isoniazid chemoprophylaxis on the advice of the ID team. The remaining 5 patients started anti-TNF based on the absence of risk factors for TB. No patient had reactivation of latent TB at follow up (range = 1 18 months). Lymphopenia was found to be associated with non-reportable cases as compared to the reported cases (median lymphocyte count unreportable = 0.4, reportable = 1.2; p = 0.015).
Conclusions: Our results demonstrate TB IGRA is a useful test to screen for latent infection before initiating anti-TNF therapy. However, a minority of results are indeterminate or unreportable. In such cases repeat testing can produce definitive results. Low lymphocyte counts in association with immunosuppression may contribute to unreportable and indeterminate results; clinical risk stratification appears to be a safe way of managing such cases in this small cohort. Results: Of 50 patients with active terminal ileal CD, the comparison of scores between SES-CD and CDAI showed significant association with Spearman's rank correlation coefficient (P < 0.01). There was statistically significant correlation between the wall thickness and SES-CD (P < 0.0001) as well as CDAI (P < 0.001), respectively, but no significant correlation between the wall thickness and the C-reactive protein (CRP) was found (P = 0.43). Moreover, we found that the wall thickness was preferential to predict the disease severity in the terminal ileal CD. Conclusions: MSCTE, in combination with ileocolonoscopy, is reliable to identify the disease severity in CD patients, and provides more accurate approach in the diagnosis and treatment. 
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